Top Links

Articles Related to Radiation Therapy

Radiation Dose to Oesophagus in Breast Cancer Patients Receiving Radiation Therapy: A Retrospective Study

Background: Breast cancer is the most common cancer in women worldwide. Management of Breast cancer requires multidisciplinary team approach (viz, Surgery, Chemotherapy, Radiation therapy, Hormonal therapy & Targeted therapy). Radiotherapy reduces the risk of breast cancer mortality for women after breast conserving surgery and for women after mastectomy for node-positive disease. One of the organs at risk in breast cancer therapy is esophagus. As such, there is potential to expose greater volumes of esophagus to radiation. This may result in increased frequency and severity of acute radiation esophagitis during treatment. Aims and Objectives: To evaluate dosimetric parameters such as mean dose (Dmean) maximum dose (Dmax) which may influence the incidence and severity of esophagitis in breast cancer patients receiving radiotherapy. Material and Methods: Treatment plans of post mastectomy patients who had already received adjuvant RT of dose 50 Gy in 25 # over 5 weeks to the chest wall along with Supraclavicular field (SCF) using 3-Dimensional Conformal Radiation Therapy (3D CRT) and Intensity Modulated Radiation Therapy (IMRT) were selected. Mean dose (Dmean) and maximum dose (Dmax) to esophagus was assessed. Results: Dosimetric parameters assessed are Dmean and Dmax. Dmean assessed up to less than or equal to 11Gy and Dmax assessed upto less than or equal to 34Gy. The average of Dmean in this study is 8.34Gy which is within normal limits of prescribed dose. The mean Of Dmax in this study is 24.80Gy which is in limits of prescribed dose. Conclusion: Increased dose to esophagus in observed when IMRT is used especially when supraclavicular or internal mammary nodes are involved. Routine contouring of esophagus and planning accordingly may reduce oesophageal dose and acute oesophageal toxicity.
View complete article: PDF  |  Full-text

Tomotherapy Treatment of Chronic Lymphocytic Leukemia and Ocular Lymphoma

A sixty-five-years-old male patient with history of non-Hodgkin’s lymphoma of the right orbit and a fifty-years-old female patient with chronic lymphocytic leukemia with peripheral lymphocytosis were treated on TomoTherapy. In the first case, a 1 cm beam was used for planning a delivery of 30.6 Gy in 17 fractions with a sequential boost of 9 Gy in 5 fractions. Tumor involvement of the ipsilateral lens and lacrimal gland in the planning target volume necessitated a compromise between preserving patient’s vision and delivery of tumoricidal dose to the target. In the second case, 30 Gy in 20 fractions delivery was planned with a 2.5 cm beam. The tumor extended anteriorly and this technique allowed sparing more orbital tissue and required a high modulation factor.
View complete article: PDF  |  Full-text

Paediatric Radiotherapy in Morocco

In Morocco, through the finding of the Casablanca population-based registry, all cancers are estimated at 35000 new cases par year and 3.2% are aged less or equal 20 years.
View complete article: PDF  |  Full-text

Image-Guided Radiotherapy Using MV for Prostate Cancer: A Correlation Analysis between Electronic Portal Imaging with Fiducial Markers and Cone Beam CT

IGRT combined with three-dimensional conformal radiation therapy (3D CRT) and intensity-modulated radiation therapy (IMRT) is gaining quick acceptance in radiotherapy treatment of prostate cancer [1-4]. The advantage of this technique is that it localizes the target volume accurately, thus increasing precision in treatment delivery.
View complete article: PDF  |  Full-text

Phase II Trial of Lower Dose Bevacizumab and Irinotecan in Relapsed High Grade Gliomas

Relapsed high-grade gliomas (HGG) respond poorly to known chemotherapeutic agents with a median survival of 3 to 6 months. Several phase II trials of Bevacizumab for salvage therapy, reported excellent response rates. The optimal dose of Bevacizumab in GBM has not been defined to date. We performed a prospective phase II trial of bevacizumab using 5 mg/kg every 2 weeks.
View complete article: PDF  |  Full-text

Targeted Approach for Prostate Cancer Treatment: Synthesis and Characterization of Docetaxel-Loaded Perfluorocarbon Nanodroplets

The purpose of this study is to synthesize and characterize nanodroplets, loaded with docetaxel for treatment of prostate cancer under MR-guided focused ultrasound. Water insoluble docetaxel encapsulated in nanodroplets is expected to be delivered into tumors with greater efficiency while minimizing drug related systemic toxicities when used in combination with focused ultrasound. The sequence of our studies toward development and characterization of docetaxel-loaded nanodroplets is as follows. First, we developed methods for synthesis of ultrasound-responsive, docetaxel-loaded nanodroplets (Doc-nd) by a solid dispersion technique. Secondly, we characterized Doc-nd by its morphology and size distributions using a dynamic light scattering (DLS) method.
View complete article: PDF  |  Full-text


Editorial Board Members Related to Radiation Therapy

Lili Chen

Associate Professor
Department of Radiation Oncology
Fox Chase Cancer Center
United States

Chang Ming Charlie Ma

Professor
Department of Radiation Oncology
Fox Chase Cancer Center
United States

Tamer Atif Mohamed Dawod

Associate Professor
Faculty of Medicine
Mansoura University
Egypt
Submit Manuscript


Open Access Journals

View All Journals